MMP-9 triggered self-assembly of doxorubicin nanofiber depots halts tumor growth

Biomaterials. 2016 Aug:98:192-202. doi: 10.1016/j.biomaterials.2016.04.039. Epub 2016 Apr 30.

Abstract

A central challenge in cancer care is to ensure that therapeutic compounds reach their targets. One approach is to use enzyme-responsive biomaterials, which reconfigure in response to endogenous enzymes that are overexpressed in diseased tissues, as potential site-specific anti-tumoral therapies. Here we report peptide micelles that upon MMP-9 catalyzed hydrolysis reconfigure to form fibrillar nanostructures. These structures slowly release a doxorubicin payload at the site of action. Using both in vitro and in vivo models, we demonstrate that the fibrillar depots are formed at the sites of MMP-9 overexpression giving rise to enhanced efficacy of doxorubicin, resulting in inhibition of tumor growth in an animal model.

Keywords: Cancer therapy; MMP; Morphology transition; Peptides; Self-assembly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use*
  • Drug Carriers / chemistry
  • Humans
  • Matrix Metalloproteinase 9 / metabolism*
  • Mice, Nude
  • Micelles
  • Nanofibers / chemistry*
  • Nanofibers / ultrastructure
  • Neoplasm Invasiveness
  • Neoplasms / drug therapy*
  • Neoplasms / pathology*
  • Peptides / pharmacology

Substances

  • Drug Carriers
  • Micelles
  • Peptides
  • Doxorubicin
  • Matrix Metalloproteinase 9